Jeremy Grantham's EW Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 14,578 shares of Edwards Lifesciences Corporation (EW) worth $1.13 M, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in EW, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2014, adding 684,000 shares. Largest reduction occurred in Q3 2020, reducing 440,385 shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by Jeremy Grantham
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +336,606 | Add 0.00% | 336,600 | $11.20 |
| Q3 2013 | +97,200 | Add 28.88% | 433,800 | $11.60 |
| Q4 2013 | -25,878 | Reduce 5.97% | 407,922 | $10.96 |
| Q1 2014 | -87,246 | Reduce 21.39% | 320,676 | $12.36 |
| Q2 2014 | +684,000 | Add 213.30% | 1 M | $14.31 |
| Q3 2014 | -100,686 | Reduce 10.02% | 903,990 | $17.02 |
| Q4 2014 | -139,176 | Reduce 15.40% | 764,814 | $21.23 |
| Q1 2015 | +39,600 | Add 5.18% | 804,414 | $23.74 |
| Q2 2015 | -42,000 | Reduce 5.22% | 762,414 | $23.74 |
| Q3 2015 | -14,694 | Reduce 1.93% | 747,720 | $23.69 |
| Q4 2015 | -102,366 | Reduce 13.69% | 645,354 | $26.33 |
| Q1 2016 | -197,370 | Reduce 30.58% | 447,984 | $29.40 |
| Q2 2016 | -447,984 | Sold Out | 447,984 | $0.00 |
| Q3 2020 | +7,599 | New Buy | 7,599 | $79.88 |
| Q4 2020 | +179,064 | Add 2356.42% | 186,663 | $91.23 |
| Q1 2021 | -152,900 | Reduce 81.91% | 33,763 | $83.64 |
| Q2 2021 | -33,763 | Sold Out | 33,763 | $0.00 |
| Q1 2022 | +6,082 | New Buy | 6,082 | $117.72 |
| Q2 2022 | -6,082 | Sold Out | 6,082 | $0.00 |
| Q4 2022 | +3,000 | New Buy | 3,000 | $74.61 |
| Q1 2023 | -3,000 | Sold Out | 3,000 | $0.00 |
| Q1 2025 | +26,591 | New Buy | 26,591 | $72.48 |
| Q2 2025 | -26,591 | Sold Out | 26,591 | $0.00 |
| Q3 2025 | +14,578 | New Buy | 14,578 | $77.77 |
Jeremy Grantham's Edwards Lifesciences Corporation Investment FAQs
Jeremy Grantham first purchased Edwards Lifesciences Corporation (EW) in Q2 2013, acquiring 336,600 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Edwards Lifesciences Corporation (EW) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's largest addition to Edwards Lifesciences Corporation (EW) was in Q2 2014, adding 1,004,676 shares worth $14.37 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 14,578 shares of Edwards Lifesciences Corporation (EW), valued at approximately $1.13 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Edwards Lifesciences Corporation (EW) represents approximately 0.00% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's peak holding in Edwards Lifesciences Corporation (EW) was 1,004,676 shares, as reported at the end of Q2 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.